Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06223269 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting
A Phase 3 study of Wound Heal and Burns Degree Third, sponsored by XenoTherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT06223269 is a Phase 3 study of Wound Heal and Burns Degree Third that is actively recruiting participants, run by XenoTherapeutics. The registered enrollment target is 50 participants, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06223269, a Phase 3 study of Wound Heal and Burns Degree Third, is actively recruiting participants, sponsored by XenoTherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.
Conditions Studied
Interventions
- DRUG Skin Xenotransplant
- PROCEDURE Autograft(ing)
Study Locations (4)
Arizona
- Arizona Burn Center Valleywise Health - Phoenix
Georgia
- JMS Burn Center at Doctors Hospital - Augusta
Maine
- MaineHealth Maine Medical Center - Portland
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2026-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06223269
The ClinicalTrials.gov registry entry for NCT06223269 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 23 other Wound Heal trials with a reported enrollment target (58% lower). The listed sponsor is XenoTherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 2 interventions - of which Skin Xenotransplant is the first listed.
NCT06223269 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Georgia, Maine.
Frequently Asked Questions
What is clinical trial NCT06223269 about?
NCT06223269 is a clinical study titled "Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting". To evaluate the safety and efficacy of realSKIN® to provide complete wound closure of mixed-depth, full-thickness burn wounds as an alternative treatment to autografting.
What is the current status of trial NCT06223269?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-05-09. Estimated completion is 2026-01.
What conditions does trial NCT06223269 study?
This clinical trial studies the following conditions: Wound Heal, Burns Degree Third, Burn (Disorder), Burn Degree Second, Thermal Burn.
What interventions are being tested in trial NCT06223269?
The interventions under investigation include: Skin Xenotransplant (DRUG), Autograft(ing) (PROCEDURE).
Who is sponsoring clinical trial NCT06223269?
This trial is sponsored by XenoTherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06223269 being conducted?
This trial has 4 study locations across Arizona, Georgia, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk Fractures
RECRUITING · Phase 3
-
Tissue Repair Gel in Venous Leg Ulcers (US)
RECRUITING · Phase 3
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
-
INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.